Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $13
Portfolio Pulse from jenniferd'souza@benzinga.com
Lake Street analyst Eric Martinuzzi has maintained a 'Buy' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $18 to $13.
August 15, 2023 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
OptimizeRx's price target has been lowered from $18 to $13 by Lake Street, though the 'Buy' rating is maintained.
The news directly pertains to OptimizeRx (OPRX) as the company's price target has been lowered by Lake Street. However, the 'Buy' rating is maintained which indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100